Skip to main content
BoF Logo

Agenda-setting intelligence, analysis and advice for the global fashion community.

Zepbound Beats Wegovy in First Head-to-Head Trial

Eli Lilly’s GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk’s Wegovy, according to the trial results.
Wegovy injections
The findings come days after CVS Health’s decision to drop Zepbound from some lists of medicines it covers for reimbursement, instead favouring Wegovy. (Shutterstock)

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk’s Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.

In This Article
Organisations

© 2026 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

More from Beauty
Analysis and advice on the fast-evolving beauty business.

Can Mikayla Nogueira Sell Fragrance, Too?

The beauty influencer is hoping her 20 million-strong following can cut through the category’s oversaturation with Only Sunshine, a tropical scent launched with indie brand Snif.


Ulta Beauty Joins TikTok Shop

Ulta Beauty becomes the first US specialty beauty retailer to launch on TikTok Shop, making the case for partnership rather than competition with the platform’s beauty e-commerce business.


view more
Latest News & Analysis
Unrivalled, world class journalism across fashion, luxury and beauty industries.
VIEW MORE
Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON